You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,001,602

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,001,602

Title:	Use of botulinum toxin therapy for urinary incontinence and related disorders
Abstract:	The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s):	Schmidt; Richard A. (Arvada, CO)
Assignee:	The Regents of the University of Colorado (Boulder, CO)
Application Number:	10/685,995
Patent Claims:	1. A method for treating urinary incontinence in a patient, the method comprising the step of administering to a patient with urinary incontinence a botulinum toxin, thereby treating the urinary incontinence. 2. The method of claim 1, wherein the patent is a human. 3. The method of claim 1, wherein the patient is a human female. 4. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A. 5. The method of claim 1, wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a pill, a troche, a suppository, a suspension, and a solution. 6. The method of claim 1, wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of a cream, a suspension and an emulsion. 7. The method of claim 1, wherein the botulinum toxin is injected into the urinary tract or the bladder of the patient in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, an emulsion, a suspension, and a solution. 8. The method of claim 1, wherein the patient has urge incontinence. 9. The method of claim 1, wherein administration of the botulinum toxin results in increased bladder capacity in the patient. 10. The method of claim 1, wherein administration of the botulinum toxin results in reduced bladder spasticity in the patient. 11. A method for treating urinary incontinence in a human patient, the method comprising the step of administering to a human patient with urinary incontinence a botulinum toxin type A, thereby treating the urinary incontinence. 12. The method of claim 1, wherein the patient has incontinence resulting from traumatic injury. 13. The method of claim 1, wherein the patient has incontinence resulting from injury to the vertebrae.

Details for Patent 7,001,602

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allergan, Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	12/09/1991	⤷ Try a Trial	2017-07-15
Allergan, Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	12/09/1991	⤷ Try a Trial	2017-07-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,001,602

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Austria	314085	⤷ Try a Trial
Austria	320815	⤷ Try a Trial
Austria	339220	⤷ Try a Trial
Austria	448792	⤷ Try a Trial
Austria	552006	⤷ Try a Trial
Australia	2005234633	⤷ Try a Trial
Australia	743085	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.